PharmGKB summary: voriconazole pathway, pharmacokinetics
暂无分享,去创建一个
[1] Julia M. Barbarino,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy , 2018, Clinical pharmacology and therapeutics.
[2] Michelle Whirl-Carrillo,et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC) , 2016, Genetics in Medicine.
[3] S. Zhai,et al. Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis , 2016, European Journal of Clinical Pharmacology.
[4] S. Arron,et al. Association of CYP2C19 *17/*17 Genotype With the Risk of Voriconazole-Associated Squamous Cell Carcinoma. , 2016, JAMA dermatology.
[5] A. Vinks,et al. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[6] L. Thiberville,et al. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections. , 2016, International journal of antimicrobial agents.
[7] S. Arron,et al. Voriconazole Exposure and Risk of Cutaneous Squamous Cell Carcinoma, Aspergillus Colonization, Invasive Aspergillosis and Death in Lung Transplant Recipients , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[8] Y. Tanigawara,et al. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole , 2015, Journal of clinical pharmacology.
[9] M. Andréjak,et al. High metabolic N‐oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype , 2015, British journal of clinical pharmacology.
[10] N. Ledeboer,et al. CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. , 2015, Diagnostic microbiology and infectious disease.
[11] J. Bakker,et al. Gain-of-function single nucleotide variants of the CYP2C19 gene (CYP2C19*17) can identify subtherapeutic voriconazole concentrations in critically ill patients: a case series , 2015, Intensive Care Medicine.
[12] K. Sangkuhl,et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors , 2015, Clinical pharmacology and therapeutics.
[13] T. Ashavaid,et al. Correlation of CYP2C19 genotype with plasma voriconazole levels: a preliminary retrospective study in Indians , 2015, International Journal of Clinical Pharmacy.
[14] Joo-Youn Cho,et al. A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles , 2015, Drug design, development and therapy.
[15] I. Thompson,et al. Finasteride Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial , 2015, PloS one.
[16] K. Thursky,et al. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. , 2015, The Journal of antimicrobial chemotherapy.
[17] Ya-jing Zhai,et al. Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole , 2015, European Journal of Clinical Microbiology & Infectious Diseases.
[18] N. Maeda,et al. Pharmacokinetics and Safety of Voriconazole Intravenous-to-Oral Switch Regimens in Immunocompromised Japanese Pediatric Patients , 2014, Antimicrobial Agents and Chemotherapy.
[19] J. Xing,et al. Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections. , 2014, International journal of antimicrobial agents.
[20] F. D. De Rosa,et al. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. , 2014, Pharmacogenomics.
[21] Y. Daali,et al. Therapeutic drug monitoring of voriconazole: a case report of multiple drug interactions in a patient with an increased CYP2C19 activity , 2014, AIDS Research and Therapy.
[22] M. Relling,et al. Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes. , 2014, Pharmacogenomics.
[23] Julie A. Johnson,et al. CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics? , 2014, Pharmacotherapy.
[24] H. Yamazaki,et al. Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype. , 2014, The Journal of infectious diseases.
[25] Ze-yan Zhong,et al. Impact of the CYP3A5, CYP3A4, COMT, IL-10 and POR Genetic Polymorphisms on Tacrolimus Metabolism in Chinese Renal Transplant Recipients , 2014, PloS one.
[26] S. Park,et al. Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population , 2013, Infection & chemotherapy.
[27] J. Mega,et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.
[28] Yoko Furukawa-Hibi,et al. Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children , 2013, Journal of pediatric hematology/oncology.
[29] R. Danner,et al. Pharmacokinetics of Intravenous Voriconazole in Obese Patients: Implications of CYP2C19 Homozygous Poor Metabolizer Genotype , 2013, Pharmacotherapy.
[30] D. Fredricks,et al. Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events , 2013, BMC Infectious Diseases.
[31] M. Krajinovic,et al. Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency. , 2012, Pharmacogenomics.
[32] R. Altman,et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8 , 2012, Pharmacogenetics and genomics.
[33] S. Klein,et al. A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine , 2012, British journal of clinical pharmacology.
[34] R. Altman,et al. PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19 , 2012, Pharmacogenetics and genomics.
[35] Joo-Youn Cho,et al. Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers , 2012, Journal of clinical pharmacology.
[36] C. Lass‐Flörl. Triazole Antifungal Agents in Invasive Fungal Infections , 2011, Drugs.
[37] W. Wilson,et al. Prolonged half‐life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction , 2011, Mycoses.
[38] A. Soubani,et al. Pulmonary aspergillosis: a clinical review , 2011, European Respiratory Review.
[39] D. Booth,et al. Voriconazole toxicity related to polymorphisms in CYP2C19 , 2011, Internal medicine journal.
[40] D. Tregouet,et al. Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients , 2011, European Journal of Clinical Pharmacology.
[41] Wei-Hua Wu,et al. Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism , 2010, European Journal of Clinical Pharmacology.
[42] N. Irvine,et al. Investigation into UDP-Glucuronosyltransferase (UGT) Enzyme Kinetics of Imidazole- and Triazole-Containing Antifungal Drugs in Human Liver Microsomes and Recombinant UGT Enzymes , 2010, Drug Metabolism and Disposition.
[43] W. Haefeli,et al. Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype. , 2009, British journal of clinical pharmacology.
[44] Kazuaki Matsumoto,et al. Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes. , 2009, International journal of antimicrobial agents.
[45] Wei Zhang,et al. Lack of Effect of Ginkgo biloba on Voriconazole Pharmacokinetics in Chinese Volunteers Identified as CYP2C19 Poor and Extensive Metabolizers , 2009, The Annals of pharmacotherapy.
[46] Honghao Zhou,et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers , 2009, European Journal of Clinical Pharmacology.
[47] W. Haefeli,et al. CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole , 2009, Journal of clinical pharmacology.
[48] D. Benjamin,et al. Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes , 2008, Drug Metabolism and Disposition.
[49] Melissa D. Johnson,et al. Current Options in Antifungal Pharmacotherapy , 2008, Pharmacotherapy.
[50] Thierry Buclin,et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[51] P. Sonneveld,et al. Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. , 2007, The Journal of antimicrobial chemotherapy.
[52] M. Shimizu,et al. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. , 2007, Biochemical pharmacology.
[53] G. Mikus,et al. Safety of Voriconazole in a Patient with CYP2C9*2/CYP2C9*2 Genotype , 2006, Antimicrobial Agents and Chemotherapy.
[54] Gerd Mikus,et al. Potent cytochrome P450 2C19 genotype–related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir , 2006, Clinical pharmacology and therapeutics.
[55] M. Nakashima,et al. Pharmacokinetics of Voriconazole and Cytochrome p450 2C19 Genetic Status , 2004, Clinical pharmacology and therapeutics.
[56] N. Wood,et al. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[57] D A Smith,et al. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[58] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Posaconazole , 2010, Clinical pharmacokinetics.
[59] H. Derendorf,et al. Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.